Compared to controls, the CD8+/CD4+ T cell ratio in TME was significantly increased by CpG/R848/Adpgk-codeliverying NPs (CRA-NPs) + an anti-programmed death-1 antibody (αPD-1), indicating a positive response to tumor therapy (Fig. 2F). The gene discussed is CD8A; the disease is neoplasm.